MiNK Therapeutics, Inc.

Good day, everyone, and welcome to the Mink Therapeutics fourth quarter 2023 financial results. Today's call is being recorded. All lines have been placed on mute to prevent any background noise. And after the speaker's remarks, there will be a question and answer session. If you would like to ask a question during that time, simply press star 1 on your telephone keypad. If you would like to withdraw your question, it is star 1 again. I would now like to turn the conference over to Zach Arman, head of investor relations. Please go ahead.

Thank you, Lisa. And thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements, including statements regarding our clinical development, regulatory and commercial plans, and timelines, as well as timelines for data release and partnership opportunities, among other updates. These statements are subject to risks and uncertainties, and we refer you to our SEC filings available on our website for more details on these risks. Joining me today are Dr. Jennifer Buell, President and Chief Executive Officer, Christine Klaskin, Principal Financial and Accounting Officer, and Dr. Mark Van Dyke, Chief Scientific Officer. Dr. Joy Zhu, Head of CMC, is also here for any questions. Now, I'd like to turn the call over to Dr. Buell to highlight our progress in 2023 and to speak to our outlook for 2024.

Thank you very much, Zach.